Volume 9, Number 1—January 2003
Research
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Gillian D. Sanders*
and Al V. Taira*
and Al V. Taira*
Table 2
Intermediate health outcomes of HPV vaccinationa,b
| Outcome | HPV vaccination | No vaccination | Lifetime cases averted | No. needed to vaccinate to prevent one case |
|---|---|---|---|---|
| HPV | 1,460,699 | 1,684,954 | 224,255 | 9 |
| SIL | 417,549 | 530,259 | 112,710 | 18 |
| Cervical cancer | 13,374 | 16,690 | 3,316 | 600 |
| Cervical-cancer deaths | 5,121 | 6,461 | 1,340 | 1,484 |
aAssumes program that successfully administers a vaccine against high-risk HPV to the current U.S. cohort of 12-year-old girls.
bHPV, Human papillomavirus; SIL, squamous intraepithelial lesions.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.